Good morning, everybody. My name is Kyahn Williamson, SVP of Investor Relations and Corporate Communications at Telix. And we're very pleased to welcome you today to our investor call and webcast to ...
Stockhead on MSN
Health check: Telix jumps first hurdle with its advanced prostate cancer therapy trial
In welcome good news, Telix says the first stage of its pivotal prostate cancer therapeutic trial has hit its desired safety ...
The results from Part 1 are consistent with prior clinical studies of this first-in-class lutetium radio antibody-drug conjugate (rADC) therapy.
一些您可能无法访问的结果已被隐去。
显示无法访问的结果